PureTech Founded Entity Akili Announces Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan
Portfolio Pulse from Benzinga Newsdesk
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC) and its Founded Entity Akili, Inc. (NASDAQ:AKLI) announced that Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 for marketing approval in Japan. SDT-001 is a localized version of Akili's EndeavorRx®, the first prescription digital therapeutic approved by the FDA for pediatric ADHD patients aged 8 to 17 in the US.
February 27, 2024 | 8:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akili, Inc.'s submission of SDT-001 for marketing approval in Japan, in partnership with Shionogi & Co. Ltd, marks a pivotal moment in the company's expansion and the global adoption of digital therapeutics for ADHD.
Akili's submission of SDT-001 for marketing approval in Japan, through its partnership with Shionogi, represents a critical step in the company's strategy to expand its digital therapeutic solutions globally. This development is likely to be viewed positively by investors, potentially leading to an uptick in Akili's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 95
POSITIVE IMPACT
PureTech's Founded Entity Akili's partnership with Shionogi & Co. Ltd for the Japanese market submission of SDT-001 represents a significant step in global expansion and potential revenue growth.
The submission of SDT-001 for marketing approval in Japan by Shionogi, in partnership with Akili, a PureTech Founded Entity, indicates a significant step towards global market expansion and potential revenue growth for PureTech. This move could positively impact investor sentiment and PureTech's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90